朗姿股份40天内借款3.6亿元

Core Viewpoint - Langzi Co., Ltd. has been actively seeking bank loans to support its daily operational cash flow, indicating a focus on maintaining liquidity amid its expansion in the medical aesthetics sector [2][3]. Group 1: Loan Applications - On August 5, Langzi Co., Ltd. announced a loan application of 160 million yuan from Hangzhou Bank, following a previous application for 10 million yuan and 1 million yuan from other banks, totaling 360 million yuan in loans applied for within 40 days [2]. - Since 2025, Langzi has issued 15 announcements related to loan guarantees, including applications for bank credit lines and working capital loans, with a total borrowing amount of 232 million yuan in 2024 alone [2]. Group 2: Purpose of Loans - The company stated that the recent bank loans are primarily for daily operational cash flow, including employee salaries and supplier payments, with some funds potentially allocated for acquisition loans [3]. - The company has set a total external guarantee limit of 3.05 billion yuan for 2025, with different limits based on the subsidiaries' debt ratios [3]. Group 3: Financial Health - As of August 5, 2025, Langzi's total external guarantee balance is approximately 1.17 billion yuan, with 10 million yuan guaranteed for subsidiaries with a debt ratio exceeding 70% [4]. - The company has seven subsidiaries in the medical aesthetics sector with debt ratios above 70%, the highest being Chengdu Gaoxin Milan Baiyu Medical Aesthetic Hospital at 133.08% [4]. Group 4: Business Performance - Langzi Co., Ltd. transitioned into the medical aesthetics sector in 2016 and currently operates multiple brands across various cities, contributing significantly to its revenue [5]. - From 2022 to 2024, the company's debt ratio increased from 49.1% to 57.4%, with 2024 revenues reported at 5.691 billion yuan, a slight decrease of 0.24% year-on-year, while net profit increased by 1.38% to 257 million yuan [5]. - The medical aesthetics business generated 2.78 billion yuan in revenue in 2024, accounting for approximately 49% of the company's total revenue, with a 3.47% year-on-year growth [5].